clinical

Marengo Therapeutics Announces First Patient Dose in Phase 1/2 Clinical Trial of Its Novel TCR Vβ-Targeted Antibody Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy | DNA, RNA and cells

Marengo Therapeutics Announces First Patient Dose in Phase 1/2 Clinical Trial of Its Novel TCR Vβ-Targeted Antibody Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy details Category: DNA RNA and cells Posted on Saturday, January 28, 2023 at 6:33 pm Visit: 132 The START-001 study uses a tissue-agnostic biomarker-enriched approach to evaluate …

Marengo Therapeutics Announces First Patient Dose in Phase 1/2 Clinical Trial of Its Novel TCR Vβ-Targeted Antibody Fusion Molecule STAR0602, in Cancer Patients Refractory to Anti-PD1 Therapy | DNA, RNA and cells Read More »

Pepromene Bio, Inc. announced a complete response in the first patient treated in the phase 1 B-cell non-Hodgkin’s lymphoma (B-NHL) clinical trial PMB-CT01 (BAFFR-CAR T cells) at City of Hope

IRVINE, California, December 20, 2022 /CNW/ — PeproMene Bio, Inc., a clinical biotechnology company developing novel therapies for the treatment of cancer and immune disorders, today announced that the first patient has been treated for stage 1 relapsed or refractory B-cell non-Hodgkin’s lymphoma (r /r B-NHL) clinical trial PMB-CT01 (BAFFR-CAR T cells) achieved a complete …

Pepromene Bio, Inc. announced a complete response in the first patient treated in the phase 1 B-cell non-Hodgkin’s lymphoma (B-NHL) clinical trial PMB-CT01 (BAFFR-CAR T cells) at City of Hope Read More »